Cancer antigen prioritization: A road map to work in defining vaccines against specific targets. A point of view

Frontiers in Oncology

Volumn 2 JUN, Issue , 2012, Pages

  Gomez, Daniel E ^a   Vázquez, Ana María ^b   Alonso, Daniel F ^a  

^a UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

^b CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CANCER VACCINE; EPITOPE; RACOTUMOMAB; SIPELEUCEL T; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

CARCINOGENICITY; DRUG EFFICACY; DRUG SPECIFICITY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; NOTE; PATIENT SELECTION; PROSTATE CANCER; PROTEIN EXPRESSION; RESEARCH PRIORITY; SCORING SYSTEM; SEQUENCE HOMOLOGY;

EID: 84890715358     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2012.00066     Document Type: Note

References (10)

1. Bhattacharya-Chatterjee, M., Chatterjee, S. K., and Foon, K. A. (2002). Anti-idiotype antibody vaccine therapy for cancer. Expert Opin. Biol. Ther. 8, 869-881.
2. Bot, A. (2010). The landmark approval of Provenge, what it means to immunology and "in this issue": the complex relation between vaccines and autoimmunity. Int. Rev. Immunol. 29, 235-238.
3. Busham, N., and Rai, K. (2004). Strategic Decision Making: Applying the Analytic Hierarchy Process. London: Springer-Verlag.
4. Cheever, M. A., Allison, J. P., Ferris, A. S., Finn, O. J., Hastings, B. M., Hecht, T. T., Mellman, I., Prindiville, S. A., Viner, J. L., Weiner, L. M., and Matrisian, L. M. (2009). The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research. Clin. Cancer Res. 15, 5323-5337.
5. Dolan, J. G., and Iadarola, S. (2008). Risk communication formats for low probability events: an exploratory study of patients preferences. BMC Med. Inform. Decis. Mak. 8, 14-23.
6. Fernandez, L. E., Gabri, M. R., Guthmann, M. D., Gomez, R. E., Gold, S., Fainboim, L., Gomez, D. E., and Alonso, D. F. (2010). NGcGM3 ganglioside: a privileged target for cancer vaccines. Clin. Dev. Immunol. 2010, 814397.
7. Forman, E. H., and Gass, S. I. (2010). The analytical hierarchy process-an exposition. Oper. Res. 49, 235-238.
8. Katsumura, Y., Yasunaga, H., Imamura, T., Obe, K., and Oyama, H. (2008). Relationship between risk information on total colonoscopy and patient preferences for colorectal cancer screening options: analysis using the analytic hierarchy process. BMC Health Serv. Res. 21, 106-114.
9. Lang, J. M., Andrei, A. C., and Mc Nee, D. G. (2009). Prioritization of cancer antigens: keeping the target in sight. Expert Rev. Vaccines 8, 1657-1661.
10. Olson, W. C., Heston, W. D., and Rajasejaran, A. K. (2007). Clinical trials of cancer therapies targeting prostate-specific membrane antigens. Rev. Recent Clin. Trials 2,182-190.